)
Business philosophy23 Apr 2026
Greg Foran: The New CEO of Kroger
How Greg Foran rose from store floor to CEO of Kroger, led Walmart's turnaround, and built a leadership style focused on execution.
Aprea Therapeutics
Aprea Therapeutics (APRE) investor relations material
Aprea Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary22 Apr, 2026
Company overview and business model
Clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers using synthetic lethality approaches.
Pipeline includes WEE1 inhibitor (APR-1051), ATR inhibitor (ATRN-119), and early-stage DYRK1A/B inhibitor (APR-1602).
Focus on matching treatments to specific genetic mutations to maximize effectiveness and minimize side effects.
Shifted focus to assets acquired from Atrin Pharmaceuticals and in-house developments after May 2022 acquisition.
Financial performance and metrics
Audited financials for 2024 and 2025 include an explanatory paragraph about substantial doubt regarding ability to continue as a going concern.
As of March 31, 2026, 11,982,776 shares of common stock were outstanding.
Use of proceeds and capital allocation
No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for clinical trials, working capital, and general corporate purposes.
Actual expenditures will depend on clinical trial progress and operational cash needs; management retains broad discretion over use of funds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aprea Therapeutics
- APR-1051 demonstrates early efficacy and safety as a selective WEE1 inhibitor in targeted cancers.APRE
Corporate presentation20 Apr 2026 - Key votes include director elections, a reverse stock split, and executive compensation approval.APREProxy filing20 Apr 2026
- Shelf registration filed amid auditor's going concern warning and strong scientific leadership.APRERegistration Filing17 Mar 2026
- Clinical progress and improved financials position the company for key milestones in 2026.APREQ4 202516 Mar 2026
- Promising early data for a daily WEE1 inhibitor show efficacy and safety in targeted cancer patients.APREOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- Registering 12.6M shares for resale, with proceeds from warrants funding clinical trials amid financial risk.APRERegistration Filing20 Feb 2026
- APR-1051 demonstrates potent, selective WEE1 inhibition with a differentiated safety profile in early trials.APREStudy Update3 Feb 2026
- Ongoing trials for WEE1 and ATR inhibitors show early efficacy, with major updates due by early 2025.APREH.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025
- Registering 5.5M shares for resale, with major dilution and financial risks highlighted.APRERegistration Filing19 Dec 2025
Next Aprea Therapeutics earnings date
Q1 202613 May, 2026
Aprea Therapeutics
Next Aprea Therapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company research22 Apr 2026
Companies That Had Their IPO in 2025: The IPO Market Recovers
After years of uncertainty, 2025 marked the IPO market's return, with major listings like Klarna and Figma signaling renewed momentum.
)
Business philosophy22 Apr 2026
Benedetto Vigna: The CEO of Ferrari
An unexpected leader for Ferrari: how semiconductor expert Benedetto Vigna became CEO and why his background fits the industry's shift.
Frequently asked questions
Explore our global coverage